| Literature DB >> 24416276 |
Xinhua Qu1, Zanjing Zhai1, Xuqiang Liu1, Haowei Li1, Chuanlong Wu1, Yang Li1, Huiwu Li1, Zhenan Zhu1, An Qin1, Kerong Dai1.
Abstract
BACKGROUND: The accuracy of synovial fluid (SF) white cell count (WCC) and polymorphonuclear (PMN) cell evaluation for predicting prosthetic joint infection (PJI) at the total hip arthroplasty (THA) or total knee arthroplasty (TKA) site is unknown. Therefore, we performed a meta-analysis to summarize the diagnostic validity of SF-WCC and SF-PMN for diagnosing PJI.Entities:
Mesh:
Year: 2014 PMID: 24416276 PMCID: PMC3885622 DOI: 10.1371/journal.pone.0084751
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flowchart for study selection.
Characteristics of the 15 studies in our meta-analysis of the diagnosis of PJI using SF-WCC and SF-PMN.
| Study | Country | Patients number | Meanage (y) | Study design, Enrollment | Sample obtain | Excluded inflammatory arthropathy | Sample type | Cut-off | Sample part | Ref Standard |
| Dinneen et al, 2013 | United Kingdom | 75 | 70.3 | Prospective, NA | Preoperatively | Yes | SF WCC;SF PMN | 1590/µl; 65% | Hip or Knee | IOF, H, M |
| Cipriano et al, 2012 | United States | 871 | 65 | Prospective, Consecutive | Preoperatively or Intraoperatively | Yes | SF WCC; SF PMN | 3450/µl; 78% | Hip or Knee | IOF, H, M |
| Schwartz et al, 2012 | United States | 96 | 65 | Retrospective, Consecutive | NA | No | SF WCC; SF PMN | 6200/µL; 60% | Knee | IOF, H, M |
| Kusuma et al, 2011 | United States | 76 | 65 | Retrospective, Consecutive | Preoperatively | NA | SF WCC; SF PMN | 1102.5/µL; 71.5% | Knee | IOF, H |
| Shukla et al, 2010 | United States | 86 | 64.2 | Retrospective, Consecutive | Intraoperatively | No | SF WCC; SF PMN | 3528/µL; 79% | Hip | IOF, H, M |
| Lee et al, 2010 | Korea | 56 | 69.6 | Retrospective, NA | Preoperatively | Yes | SF WCC; SF PMN | 3800/uL; 89% | Knee | IOF, H, M |
| Schinsky et al, 2008 | United States | 220 | 64.9 | Prospective, Consecutive | Intraoperatively | Yes | SF WCC; SF PMN | 4200/mL; 80% | Hip | M, H |
| Ghanem et al, 2008 | United States | 429 | 67 | Retrospective, NA | Preoperatively | Yes | SF WCC; SF PMN;SF PMN | 1100/uL; 64%; 73% | Knee | IOF, H, M |
| Trampuz et al, 2007 | United States | 160 | 69 | Prospective, NA | Preoperatively | No | SF WCC; SF PMN | 1700/µl; 65% | Hip or Knee | IOF, H |
| Nilsdotter-Augustinsson et al, 2007 | Sweden | 54 | 71.5 | Prospective, Consecutive | Preoperatively | Yes | SF WCC | 1700/µl | Hip | M |
| Della Valle et al, 2007 | United States | 94 | 66.6 | Retrospective, Consecutive | Preoperatively | NA | SF WCC; SF PMN | 3000/mL; 65% | Knee | IOF, H, M |
| Parvizi et al, 2006 | United States | 168 | 68 | Prospective, NA | Intraoperatively | Yes | SF WCC; SF PMN | 1760/µL; 73% | Hip or Knee | IOF, M |
| Trampuz et al, 2004 | United States | 133 | 71 | Prospective, NA | Preoperatively | Yes | SF WCC; SF PMN | 1700/µl; 65% | Knee | IOF, H, M |
| Mason et al, 2003 | United States | 86 | NA | Retrospective, NA | Preoperatively | No | SF WCC; SF PMN | 2500/ml; 60% | Knee | H, M |
| Spangehl et al, 1999 | Canada | 183 | 65 | Prospective, NA | Intraoperatively | Yes | SF WCC; SF PMN | 50000/µl; 80% | Hip | IOF, H, M |
H: histological examination; IOF: Intraoperative finding; M: microbiological or laboratory examination; NA, not available; SF:Synovial fluid PMN: polymorphonuclear leukocytes; SF: synovial fluid; WCC: white cell count.
Figure 2Summary receiver-operating characteristic curves for SF-WCC (A) and SF-PMN (B).
Curves include a summary operating point for sensitivity and specificity on the curve and a 95% confidence contour ellipsoid.
Figure 3Meta-regression analyses of the sensitivity and specificity of SF-WCC.
Figure 4Likelihoor ratio scattergram for SF-WCC(A) and SF-PMN(B).
Figure 5Pre-test probabilities and likelihood ratios for SF-WCC (A) and SF-PMN (B).
With a pre-test probability of PJI of 20% (low clinical suspicion), the post-test probability of PJI, given a negative SF-WCC or SF-PMN result, is both 3%, which can be considered sufficient to rule out PJI.
Subgroup analyses for diagnosing of PJI using SF-WCC and SF-PMN.
| Number of Studies | Number of Patients | Sensitivity (95% CI) | Specificity (95% CI) | Area Under theCurve (95% CI) | Positive Likelihood Ratio (95% CI) | Negative Likelihood Ratio(95% CI) | Diagnostic Odds Ratio | |
|
| ||||||||
|
| 15 | 2,700 | 0.88 (0.81,0.93) | 0.93(0.88,0.96) | 0.96 (0.94,0.98) | 13.3 (7.7,22.8) | 0.13 (0.08,0.21) | 103 (54,197) |
|
| ||||||||
| <100 | 8 | 623 | 0.88 (0.76,0.94) | 0.93 (0.84,0.97) | 0.96 (0.94,0.97) | 12.3 (5.2,29.2) | 0.13 (0.06,0.28) | 94 (24,367) |
| ≥100 | 7 | 2,077 | 0.88 (0.75,0.94) | 0.94 (0.87,0.97) | 0.97 (0.95,0.98) | 13.7 (7.3,25.6) | 0.13 (0.07,0.26) | 104 (67,161) |
|
| ||||||||
| Prospective | 8 | 1,777 | 0.89 (0.77,0.95) | 0.94 (0.89,0.97) | 0.97 (0.95,0.98) | 14.4 (8.7,23.8) | 0.12 (0.06,0.24) | 120 (75,193) |
| Retrospective | 7 | 923 | 0.88 (0.76,0.94) | 0.92 (0.82,0.97) | 0.96 (0.93,0.97) | 11.5 (4.4,30.0) | 0.13 (0.06,0.28) | 88 (20,383) |
|
| ||||||||
| Consecutive | 7 | 1,410 | 0.90 (0.84,0.93) | 0.93 (0.88,0.96) | 0.96 (0.94,0.98) | 13.2 (7.1,24.5) | 0.11 (0.07,0.18) | 120 (41,345) |
| Not document | 8 | 1,290 | 0.87 (0.75,0.94) | 0.94 (0.86,0.97) | 0.96 (0.94,0.98) | 13.7 (6.4,29.2) | 0.14 (0.07,0.27) | 98 (54,175) |
|
| ||||||||
| Preoperative | 9 | 1,163 | 0.91 (0.82,0.95) | 0.89 (0.81,0.94) | 0.95 (0.93,0.97) | 8.2 (4.5,14.8) | 0.11 (0.06,0.21) | 75 (26,216) |
| Intraoperative | 4 | 638 | 0.77 (0.51,0.91) | 0.97 (0.93,0.99) | 0.97 (0.96,0.98) | 27.8 (11.5,67.3) | 0.24 (0.10,0.56) | 116 (41,333) |
|
| ||||||||
| Yes | 9 | 2,102 | 0.88 (0.79,0.93) | 0.93 (0.88,0.96) | 0.96 (0.94,0.98) | 13.0 (7.7,21.9) | 0.13 (0.07,0.23) | 100 (65,153) |
| No | 6 | 598 | 0.89 (0.72,0.97) | 0.94 (0.82,0.98) | 0.97 (0.95,0.98) | 13.8 (4.5,42.2) | 0.11 (0.04,0.34) | 122 (20,740) |
|
| ||||||||
| Hip | 4 | 524 | 0.73 (0.56,0.85) | 0.96 (0.93,0.98) | 0.96 (0.93,0.97) | 19.1 (11.1,33.0) | 0.28 (0.16,0.48) | 68 (39,117) |
| Knee | 7 | 970 | 0.90 (0.78,0.96) | 0.91 (0.80,0.96) | 0.96 (0.94,0.97) | 9.8 (4.1,23.3) | 0.11 (0.05,0.26) | 88 (21,381) |
|
| ||||||||
|
| 14 | 2,726 | 0.90 (0.84,0.93) | 0.88 (0.83,0.92) | 0.95 (0.93,0.96) | 7.6 (4.9,11.7) | 0.12(0.07,0.19) | 64 (27,149) |
|
| ||||||||
| <100 | 7 | 564 | 0.86 (0.74,0.92) | 0.83 (0.73,0.89) | 0.91 (0.88,0.93) | 5.0 (3.0,8.3) | 0.17 (0.09,0.34) | 28 (9,85) |
| ≥100 | 7 | 2,162 | 0.93 (0.88,0.96) | 0.92 (0.87,0.95) | 0.97 (0.95,0.98) | 11.3 (6.8,19.2) | 0.08 (0.05,0.14) | 141 (53,371) |
|
| ||||||||
| Prospective | 7 | 1,808 | 0.92 (0.88,0.94) | 0.91 (0.87,0.94) | 0.96 (0.94,0.98) | 10.0 (7.0,14.3) | 0.09 (0.06,0.13) | 108 (56,209) |
| Retrospective | 7 | 918 | 0.87 (0.75,0.93) | 0.85 (0.74,0.91) | 0.92 (0.90,0.94) | 5.7 (3.1,10.7) | 0.16 (0.07,0.27) | 36 (10,132) |
|
| ||||||||
| Consecutive | 6 | 1,438 | 0.89 (0.83,0.94) | 0.84 (0.79,0.89) | 0.93 (0.90,0.95) | 5.7 (4.1,8.1) | 0.13 (0.07,0.22) | 46 (20,106) |
| Not Available | 8 | 1,288 | 0.90 (0.85,0.94) | 0.90 (0.86,0.94) | 0.96 (0.94,0.97) | 9.5 (6.0,14.8) | 0.11 (0.07,0.17) | 87 (37,205) |
|
| ||||||||
| Preoperative | 8 | 1,109 | 0.90 (0.80,0.95) | 0.88 (0.78,0.94) | 0.95 (0.93,0.97) | 7.6 (3.8,15.1) | 0.11 (0.05,0.24) | 66 (16,267) |
| Intraoperative | 4 | 655 | 0.88 (0.80,0.93) | 0.86 (0.80,0.90) | 0.93 (0.91,0.95) | 6.3 (4.2,9.4) | 0.14 (0.08,0.24) | 44 (19,103) |
|
| ||||||||
| Yes | 8 | 2,133 | 0.91 (0.85,0.95) | 0.90 (0.82,0.94) | 0.96 (0.94,0.97) | 8.7 (4.7,16.3) | 0.10 (0.06,0.18) | 85 (27,271) |
| No | 6 | 593 | 0.88 (0.75,0.95) | 0.86 (0.78,0.92) | 0.93 (0.91,0.95) | 6.4 (3.7,11.0) | 0.14 (0.06,0.32) | 46 (13,158) |
|
| ||||||||
| Hip | 3 | 487 | 0.85 (0.79,0.89) | 0.83 (0.80,0.86) | 0.91 (0.88,0.93) | 5.1 (4.3,6.0) | 0.18 (0.13,0.26) | 28 (18,44) |
| Knee | 7 | 965 | 0.90 (0.78,0.95) | 0.88 (0.77,0.95) | 0.95 (0.93,0.97) | 7.7 (3.4,17.3) | 0.12 (0.05,0.28) | 66(13,325) |
NA, not available; PMN: polymorphonuclear leukocytes; SF: synovial fluid; WCC: white cell count.
Figure 6Funnel plots for included studies.
(A) SF-WCC; (B) SF-PMN.